Bioequivalence and Bioavailability Forum

Subject	Author	Posted	Rep.	last R.	Views
data management data management	Imph	2024-03-14 09:57	1	2024-03-14 15:47	542
homoscedasticity assumption in RSABE method heteroscedasticity in RSABE (and ABEL) heteroscedasticity in RSABE (and ABEL) homoscedasticity assumption in RSABE method Asking a pupil Asking a pupil	WinnieH	2023-08-18 08:57	5	2023-08-18 17:16	1,531
any SAS or R-macro for 3 period two sequence RSABEIs Use the one for TRTR \| RTRT RSABE R coded by Detlew ‘dlat’ for 3-period full replicate? ‘dlat’ for 3-period full replicate? Likely wrong workaround? a bit corrected workaround THX! Another attempt… complete.cases for dlat and ilat? a bit corrected workaround	Achievwin	2023-07-05 18:38	9	2023-07-10 20:43	2,095
Reference-Scaled Average Bioequivalence FDA: TRT\|RTR instead of TRR\|RTR\|RRT?	Brus	2023-06-06 12:18	1	2023-06-07 10:22	1,362
Upper confidence bound and confidence interval of RSABE	WinnieH	2023-03-21 10:58	0		1,044
Questions on understanding the 4-way RSABE method SAS code Questions on understanding the 4-way RSABE method SAS code Questions on understanding the 4-way RSABE method SAS code	WinnieH	2023-01-04 13:33	2	2023-01-04 15:12	1,995
scale average bioequivalence for parallel design Parallel design: Maybe (‼) in exceptional cases Parallel design: Maybe (‼) in exceptional cases	Mahmoud	2022-06-15 12:33	2	2022-06-15 21:26	1,872
Sample size and power	Helmut	2022-03-28 13:39	0		1,281
Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design NTIDs	Sereng	2022-01-28 19:37	3	2022-01-29 11:19	2,077
FDA: SAS-code for NTIDs FDA: SAS-code for NTIDs	Bebac user	2021-12-06 00:36	1	2021-12-06 09:55	2,242
Inter-subject variability in Full replicate design Inter-subject variability in Full replicate design Inter-subject variability in Full replicate design	MGR	2021-09-30 07:35	2	2021-09-30 13:25	2,439
If we have any methods to widen CI in parallel design with high variance drug? If we have any methods to widen CI in parallel design with high variance drug? If we have any methods to widen CI in parallel design with high variance drug?	libaiyi	2021-02-02 09:39	2	2021-02-02 10:40	2,272
95% upper bound limit as per FDA for fully replicate crossover BE study 95% upper bound limit as per FDA for fully replicate crossover BE study 0.001 > 0 0.001 > 0	yogeshla	2021-01-05 07:01	3	2021-01-05 11:33	2,474
Estimate the sample size HVD AUC (by ABE) and Cmax (by ABEL): power AUC (by ABE) and Cmax (by ABEL): power	Yura	2020-12-03 08:47	2	2020-12-04 07:11	2,215
Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits Inflated type I error: Not nice Power of the GCC framework and power of PowerTOST Sample sizes (ignoring the inflated TIE) Bug? “Feature” Inflated type I error with fixed widened limits? Inflated type I error with fixed widened limits Inflated type I error with fixed widened limits Inflated type I error with fixed widened limits Houston, we have a problem! Paradox of tolerance Οὐτοπεία ∨ Εὐτοπεία Uchronia Steampunk Dieselpunk Dieselpunk Steampunk? OT Steampunk? OT PowerTOST 1.5-2.9000 on GitHub	Helmut	2020-11-25 10:50	22	2020-12-23 11:18	6,942